Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell
• Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter.
• Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
A Preview Of Gracell Biotechnologies’s Earnings
Gracell Biotechnologies (NASDAQ:GRCL) is set to give its latest quarterly earnings report on Monday, 2023-11-13. Here’s what investors…
Gracell Biotechnologies To Present Updated Results From BCMA/CD19 Dual-Targeting FasTCAR-T GC012F In Newly Diagnosed Multiple Myeloma At The 65 American Society Of Hematology Annual Meeting & Exposition
Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma GC012F is a
Gracell Biotechnologies To Present Data Highlighting Preclinical Efficacy Of SMART CART Against Solid Tumors At Society For Immunotherapy Of Cancer 38th Annual Meeting
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained
Benzinga’s Top Ratings Upgrades, Downgrades For October 19, 2023
Upgrades According to CL King, the prior rating for Stepan Co (NYSE:SCL) was changed from Neutral to Buy.…
The Latest Analyst Ratings for Gracell Biotechnologies
Analysts have provided the following ratings for Gracell Biotechnologies (NASDAQ:GRCL) within the last quarter: Bullish Somewhat Bullish Indifferent…
Gracell Biotechnologies Reports Updated Clinical Data For FasTCAR-T GC012F For High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society Annual Meeting100% (19/19) patients achieved minimal
Gracell Biotechnologies Doses First Patient In Phase 1b/2 Clinical Trial In U.S. Evaluating GC012F For Treatment Of Relapsed/Refractory Multiple Myeloma
Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for
Gracell Biotechnologies To Present Updated Clinical Data On BCMA/CD19 Dual-Targeting FasTCAR-T GC012F In Newly Diagnosed Multiple Myeloma At The 2023 International Myeloma Society Annual Meeting
Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell
4 Analysts Have This to Say About Gracell Biotechnologies
Over the past 3 months, 4 analysts have published their opinion on Gracell Biotechnologies (NASDAQ:GRCL) stock. These analysts…